TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02836691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKG (electrocardiogram)
Description: Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKG (electrocardiogram)
Description: Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKG (electrocardiogram)
Description: Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKG (electrocardiogram)
Description: Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
Study: NCT01933477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCH-focused ART services
Description: Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
Study: NCT01437930

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: n-3 PUFA
Description: products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~1. linseed oil (20g/d)(PPM, Magdeburg)~2. echium oil (20g/d) (HARKE Nutrition)~3. microalgae powder(12g/d)(HARKE Nutrition)
Study: NCT01231074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
Study: NCT00545909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months (+ feedback)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months (- feedback)
Study: NCT02626494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcystein
Description: n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcystein
Description: n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Study: NCT01701115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block
Description: Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Study: NCT04263181

Intervention type: PROCEDURE
Intervention: Buccal swab
Description: * Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28

Intervention type: PROCEDURE
Intervention: Buccal swab
Description: * Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28

Intervention type: PROCEDURE
Intervention: Buccal swab
Description: * Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28
Study: NCT00826800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX and bevacizumab
Description: The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
Study: NCT04585087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: 6 levels of threonine intake will be provided by the protein liquid drink
Study: NCT03136003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
Study: NCT02103777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
Study: NCT00615030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
Study: NCT04263181

Intervention type: PROCEDURE
Intervention: Buccal swab
Description: * Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28

Intervention type: PROCEDURE
Intervention: Buccal swab
Description: * Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28
Study: NCT00512577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Pre-operative red blood cell transfusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Pre-operative red blood cell transfusion
Study: NCT04237272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pod System E-cig
Description: Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customizable Tank E-cig
Description: Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
Study: NCT00615030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
Study: NCT04237272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will not receive any e-cigarette
Study: NCT04511585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Great Live and Move Challenge
Description: Physical activity program for children
Study: NCT00615030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
Study: NCT03245411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
Study: NCT04566055

Intervention type: DEVICE
Intervention: AlloSure
Description: Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
Study: NCT00615030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: 50 µg twice daily delivered via dry powder inhaler (DPI)
Study: NCT03956394

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: UltraFast ultrasound
Description: The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: UltraFast ultrasound
Description: The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
Study: NCT00309855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: im and orally

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: injections

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: injections

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: injections

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrazole
Description: orally x 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Dutasteride
Description: orally x 21 days
Study: NCT01786395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UF-021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02021903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V1: HGPO + meal and V2: placebo + meal
Description: * Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: V1: placebo 75mg + meal and V2: HGPO 75mg + meal
Description: * Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP
Study: NCT03024190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
Study: NCT03136003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP
Description: The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
Study: NCT02706509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: patient will receive oral Tramadol 50 mg an hour before IUD insertion

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Verbal anesthesia
Description: patient will receive full explanation about the procedure for five minutes before IUD insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jaydess
Description: Patient will go through an insertion of Jaydess intrauterine device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Jaydess
Description: Patient will go through an insertion of Jaydess intrauterine device.
Study: NCT04404738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroPort® robot-assisted laparoscopic surgery
Description: In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: da Vinci robot-assisted laparoscopic surgery
Description: In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
Study: NCT02816060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: manual therapy with neural exercise will be applied on patients with neck pain

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: manual therapy
Description: manual therapy with neural exercise will be applied on patients with neck pain
Study: NCT05276245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Protocol of Nature Contact
Description: This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
Study: NCT02225431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride infusion
Study: NCT02268877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Medicine Physician Ultrasound
Description: An ultrasound will be performed by an emergency medicine resident or attending physician

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound will be performed by a radiology department technician

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound will be performed by a radiology department technician
Study: NCT03024190

Intervention type: OTHER
Group type: OTHER
Intervention: stretching exercise
Description: 15- min stretching exercise for upper extremity twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: 15- min stretching exercise for upper extremity twice daily
Study: NCT02626494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Study: NCT03024190

Intervention type: OTHER
Group type: OTHER
Intervention: OT rehabilitation program
Description: regular rehabilitation program for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT rehabilitation program
Description: regular rehabilitation program for 3 weeks
Study: NCT02092311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Microscopic Varicocelectomy
Description: After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal and Subinguinal varicocelectomy
Description: Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.